Current Oncology Reports

, Volume 15, Issue 3, pp 239–248

New Agents in the Arsenal to Fight Castrate-Resistant Prostate Cancer

  • Erin E. Ezzell
  • Kuang S. Chang
  • Benjamin J. George
Genitourinary Cancers (E Jonasch, Section Editor)


Prior to 2010, the treatment options for castrate-resistant prostate cancer (CRPC) were limited. In the past 3 years, four new agents have been approved by the US Food and Drug Administration for use in CRPC. These four agents differ in their mechanisms of action and highlight the progress made in our understanding of CRPC, and more importantly, provide options with proven clinical benefit. This review examines the development, investigational evolution, adverse events, and future direction of: 1) the androgen receptor inhibitor, enzalutamide, 2) androgen biosynthesis inhibitor, abiraterone, 3) novel taxane chemotherapy, cabazitaxel, and 4) autologous immunotherapeutic agent, sipuleucel-T.


Castrate-resistant prostate cancer Enzalutamide Abiraterone Sipuleucel-T Cabazitaxel Androgen receptor Chemotherapy Immunotherapy Cancer vaccine CYP17 inhibitor Androgen deprivation therapy 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Howlader, N, Noone AM, Krapcho, M, et al. SEER cancer statistics review, 1975–2009, National Cancer Institute, Bethesda, MD. Available at Accessed December 2012.
  2. 2.
    Huggins C, Stephens RE, Hodges CV. Studies on prostate cancer: the effects of castration on advanced carcinoma of the prostate. Arch Surg. 1941;43:209–23.CrossRefGoogle Scholar
  3. 3.
    NCCN clinical practice guidelines in oncology: prostate cancer. Available at Accessed Jan 2013.
  4. 4.
    Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.PubMedCrossRefGoogle Scholar
  5. 5.
    US Food and Drug Administration: enzalutamide (XTANDI capsules). Available at Accessed Jan 2013.
  6. 6.
    US Food and Drug Administration: abiraterone acetate. Available at Accessed Jan 2013.
  7. 7.
    US Food and Drug Administration: cabazitaxel. Available at Accessed Jan 2013.
  8. 8.
    US Food and Drug Administration: Provenge (sipuleucel-T). Available at Accessed Jan 2013.
  9. 9.
    Feldman BJ, Felman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45.PubMedCrossRefGoogle Scholar
  10. 10.
    Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Chen Y, Clegg NJ, Scher HI. Antiandrogens and androgen depleting therapies in prostate cancer: novel agents for an established target. Lancet Oncol. 2009;10:981–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in the metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447–54.PubMedCrossRefGoogle Scholar
  13. 13.
    Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66:2815–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Jung ME, Ouk S, Yoo D, et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer. J Med Chem. 2010;53:2779–96.PubMedCrossRefGoogle Scholar
  15. 15.
    Tran C, Ouk S, Clegg N, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375:1437–46.PubMedCrossRefGoogle Scholar
  17. 17.
    •• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. NEJM. 2012;367:1187–97. The results of this study led to FDA approval on enzalutamide in CRPC patients who have previously received docetaxel.PubMedCrossRefGoogle Scholar
  18. 18.
    Xtandi (enzalutamide) prescribing information. Last revised 8/2012. Available at . Accessed January 2013
  19. 19.
    U.S. National Institutes of Health. A safety and efficacy study of oral MDV3100 in chemotherapy-naïve patients with progressive metastatic prostate cancer (PREVAIL). Available at Accessed January 2013.
  20. 20.
    U.S. National Institutes of Health. Safety and efficacy study of enzalutamide versus bicalutamide in men with prostate cancer (STRIVE). Available at . Accessed January 2013.
  21. 21.
    U.S. National Institutes of Health. A study of MDV3100 versus bicalutamide in castrate men with metastatic prostate cancer. Available at Accessed January 2013.
  22. 22.
    U.S. National Institutes of Health. Safety and tolerability study of MDV3100 in combination with docetaxel in men with advanced prostate cancer. Available at . Accessed January 2013.
  23. 23.
    U.S. National Institutes of Health. A study to determine safety and tolerability of enzalutamide (MDV3100) in combination with abiraterone acetate in bone metastatic catration-resistant prostate cancer patients. Available at Accessed January 2013.
  24. 24.
    U.S. National Institutes of Health. Study of MDV3100 as a neoadjuvant therapy for patients undergoing prostatectomy for localized prostate cancer. Available at Accessed January 2013.
  25. 25.
    Huggins C, Hodges CV. Studies on prostatic cancer:I. The effect of castratrion, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol 1941, 2002;168:9–12.Google Scholar
  26. 26.
    Yap TA, Carden CP, Attard G, et al. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol. 2008;9:449–57.CrossRefGoogle Scholar
  27. 27.
    Attard G, Reid A, Yap TA, et al. Phase I clinical trial of selective inhibitor of CYP17, abiraterone acetate, confirms that castration–resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–71.PubMedCrossRefGoogle Scholar
  28. 28.
    Attard G, Alison HM, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Gregory CW, Johnson RT, Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001;61:2892–8.PubMedGoogle Scholar
  30. 30.
    Potter GA, Barrie SE, Jarman M, et al. Novel Steroidal inhibitors of human cytochrome P45017 alpha (17 alphahydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem. 1995;28:2463–71.CrossRefGoogle Scholar
  31. 31.
    Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005;96:1241–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Barie SE, Haynes BP, Potter GA, et al. Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17 alpha) inhibitors. J Steroid Biochem Mol Biol. 1997;60:347–51.CrossRefGoogle Scholar
  33. 33.
    Zytiga (abiraterone acetate) tablets, prescribing information. Horsham, PA: Janssen Biotech; December 2012. Available at: Accessed January 4, 2013.
  34. 34.
    Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025–33.PubMedCrossRefGoogle Scholar
  35. 35.
    Ryan CJ, Smith MR, Lawrence F, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received ketoconazole therapy. J Clin Oncol. 2010;28:1481–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castrastion-resistant prostate cancer. J Clin Oncol. 2010;28:1496–501.PubMedCrossRefGoogle Scholar
  37. 37.
    •• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. This study lead to the FDA approval of abiraterone for treatment of metastatic CRPC after previous chemotherapy with docetaxel.PubMedCrossRefGoogle Scholar
  38. 38.
    • Ryan CJ, Smith MR, de Bono JS, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone (AA) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [abstract LBA4518] Presented at ASCO Annual Meeting. Chicago, Illinois; June 1–5, 2012. These results lead to expanded FDA approval of abiraterone for treatment of metastatic CRPC before or after chemotherapy.Google Scholar
  39. 39.
    Melmed, S., K. S. Polonsky, P. R. Larsen, and H. M. Kronenberg. Williams textbook of endocrinology, expert consult. 12th. Section IV. Philadelphia, PA: W B Saunders Co, 2011. Print.Google Scholar
  40. 40.
    U.S. National Institute of Health. A study of abiraterone acetate plus low-dose prednisone plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed patients with high-risk, metastatic hormone-naïve prostate cancer (mHNPC). Available at: Accessed January 2013.
  41. 41.
    U.S. National Institute of Health. Abiraterone acetate and prednisone with or without dasatinib in treating patients with metastatic hormone-resistant prostate cancer. Available at: Accessed January 2013.
  42. 42.
    U.S. National Institute of Health. Combining ipilimumab with abiraterone acetate plus prednisone in chemotherapy and immunotherapy-naïve patients with progressive metastatic castration-resistant prostate cancer. Available at: Accessed January 2013.
  43. 43.
    U.S. National Institute of Health. Concurrent versus sequential treatment with sipuleucel-T and abiraterone in men with metastatic castrate resistant prostate cancer (mCRPC). Available at: Accessed January 2013.
  44. 44.
    Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59.PubMedCrossRefGoogle Scholar
  45. 45.
    Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.PubMedCrossRefGoogle Scholar
  46. 46.
    Jevtana (cabazitaxel) Injection, prescribing information. Bridgewater, NJ: Sanofi; October 2012. Available at: Accessed December 2012.
  47. 47.
    Horwitz SB, Cohen D, Rao S, Ringel I, et al. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;15:55–61.PubMedGoogle Scholar
  48. 48.
    Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2003;2:685–98.PubMedCrossRefGoogle Scholar
  49. 49.
    Sanofi-aventis. XRP6258 investigator’s brochure. Antony (France): Sanofi-aventis; 2000.Google Scholar
  50. 50.
    Archimbaud Y, Gires P, Pellerin R, et al. Pharmacokinetics of a new taxoid, 14C-TXD258, in blood, plasma, and brain of the mouse, rat, and dog. Proceedings of the American Association for Cancer Research 2000:41. Abstract 1375.Google Scholar
  51. 51.
    Cisternino S, Bourasset F, Archimbaud Y, et al. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood–brain barrier in mice and rats. Br J Pharmacol. 2003;138:1367–75.PubMedCrossRefGoogle Scholar
  52. 52.
    Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723–30.PubMedCrossRefGoogle Scholar
  53. 53.
    Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h IV infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19:1547–52.PubMedCrossRefGoogle Scholar
  54. 54.
    •• de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 2010;376:1147–54. This study led to FDA approval of cabazitaxel for metastatic hormone refractory prostate cancer patients previously treated with docetaxel.PubMedCrossRefGoogle Scholar
  55. 55.
    Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American society of clinical oncology clinical practice guidelines update. American Society of Clinical Oncology ClGuideline update. J Clin Oncol. 2011;29:4189–98.PubMedCrossRefGoogle Scholar
  56. 56.
    Cabazitazel versus docdetaxel both with prednisone in patients with metastatic castration resistant prostate cancer (FIRSTANA). March 1, 2012. Available at: Accessed January 2013.
  57. 57.
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52.PubMedCrossRefGoogle Scholar
  58. 58.
    Fang L, Ruegg CL, Brockstedt D, et al. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol. 1997;159:3113–7.Google Scholar
  59. 59.
    Valone FH, Small E, MacKenzie M, et al. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J. 2001;7 Suppl 2:S53–61.PubMedGoogle Scholar
  60. 60.
    Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894–903.PubMedGoogle Scholar
  61. 61.
    Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000;6:2175–82.PubMedGoogle Scholar
  62. 62.
    Burch PA, Groghan GA, Gastineau DA, et al. Immunotherapy (APC, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatc androgen-independent prostate cancer: a phase 2 trial. Prostate. 2004;60:197–204.PubMedCrossRefGoogle Scholar
  63. 63.
    Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patient with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089–94.PubMedCrossRefGoogle Scholar
  64. 64.
    Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670–9.PubMedCrossRefGoogle Scholar
  65. 65.
    •• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;362:411–22. This study led to FDA approval of sipuleucel T as 1st cancer immunotherapy for asymptomatic or minimally symptomatic metastatic prostate cancer.CrossRefGoogle Scholar
  66. 66.
    Hall SJ, Klotz L, Pantuck AJ, et al. Integrated safety data from 4 randomized, double-blind controlled trials of autologous cellular immunotherapy with sipuleucel-T in patient with prostate cancer. J Urol. 2011;186:877–81.PubMedCrossRefGoogle Scholar
  67. 67.
    Beer TM, Bernstein GT, Corman JM. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC) [abstract 5059]. Presented at the 43rd ASCO Annual Meeting Proceedings. Chicago, Illinois; June 1–5, 2007.Google Scholar
  68. 68.
    Common Terminology Criteria for Adverse Events v(3.0) 2006. Available at . Access January 2013.
  69. 69.
    U.S. National Institutes of Health. Sipuleucel-T as neoadjuvant treatment in prostate cancer (NeoAct). Available at Accessed January 2013.
  70. 70.
    U.S. National Institutes of Health. Provenge ™ for the treatment of hormone sensitive prostate cancer (PROTECT). Available at Accessed January 2013.
  71. 71.
    U.S. National Institutes of Health. Sequencing of sipuleucel-T in men with non-metastatic prostate cancer. Available at Accessed January 2013.

Copyright information

© Springer Science+Business Media New York (outside the USA) 2013

Authors and Affiliations

  • Erin E. Ezzell
    • 1
  • Kuang S. Chang
    • 1
  • Benjamin J. George
    • 1
  1. 1.Hematology/Oncology DepartmentSan Antonio Military Medical CenterFort Sam HoustonUSA

Personalised recommendations